Ryan D McDonald1, Babak Tofighi1, Eugene Laska2, Keith Goldfeld1, Wanda Bonilla1, Mara Flannery1, Nadina Santana-Correa1, Christopher W Johnson3, Neil Leibowitz3, John Rotrosen2, Marc N Gourevitch1, Joshua D Lee4. 1. Department of Population Health, New York University School of Medicine, United States. 2. Department of Psychiatry, New York University, United States. 3. New York City Health+Hospital Corporation, Correctional Health Services, United States. 4. Department of Population Health, New York University School of Medicine, United States; Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, United States. Electronic address: joshua.lee@med.nyu.edu.
Abstract
BACKGROUND: Extended-release naltrexone (XR-NTX) is an injectable monthly sustained-release mu opioid receptor antagonist, which blocks the typical effects of heroin and other opioid agonists. Use of XR-NTX among opioid dependent persons leaving jails and prisons is increasing despite scant high-quality evidence regarding XR-NTX's effectiveness at re-entry. METHODS: This 24-week, open-label randomized controlled trial examines the effectiveness of XR-NTX as opioid relapse prevention at release from jail (N=85) compared to enhanced treatment as usual (ETAU, N=85). A third, non-randomized, quasi-experimental naturalistic arm of participants who have newly initiated a jail-to-community methadone treatment program (MTP, N=85) allows for comparisons to a methadone standard-of-care. RESULTS: We describe the rationale, design, and primary and secondary outcomes of the study. The primary outcome is an opioid relapse event; the primary contrast is a time-to-relapse comparison of XR-NTX and ETAU over a 24-week treatment phase. Secondary outcomes are rates of: (a) post-release opioid treatment participation, (b) opioid, alcohol, and cocaine use, (c) injection drug use and HIV sexual risk behaviors, (d) overdose (fatal and non-fatal) and all-cause mortality, and, (e) re-incarceration. CONCLUSIONS:XR-NTX is a potentially important, effective treatment and relapse prevention option for a large US population of persons with opioid use disorders leaving jails. This study will estimate XR-NTX's effectiveness relative to existing standards of care, including counseling-only treatment-as-usual and methadone maintenance.
RCT Entities:
BACKGROUND: Extended-release naltrexone (XR-NTX) is an injectable monthly sustained-release mu opioid receptor antagonist, which blocks the typical effects of heroin and other opioid agonists. Use of XR-NTX among opioid dependent persons leaving jails and prisons is increasing despite scant high-quality evidence regarding XR-NTX's effectiveness at re-entry. METHODS: This 24-week, open-label randomized controlled trial examines the effectiveness of XR-NTX as opioid relapse prevention at release from jail (N=85) compared to enhanced treatment as usual (ETAU, N=85). A third, non-randomized, quasi-experimental naturalistic arm of participants who have newly initiated a jail-to-community methadone treatment program (MTP, N=85) allows for comparisons to a methadone standard-of-care. RESULTS: We describe the rationale, design, and primary and secondary outcomes of the study. The primary outcome is an opioid relapse event; the primary contrast is a time-to-relapse comparison of XR-NTX and ETAU over a 24-week treatment phase. Secondary outcomes are rates of: (a) post-release opioid treatment participation, (b) opioid, alcohol, and cocaine use, (c) injection drug use and HIV sexual risk behaviors, (d) overdose (fatal and non-fatal) and all-cause mortality, and, (e) re-incarceration. CONCLUSIONS:XR-NTX is a potentially important, effective treatment and relapse prevention option for a large US population of persons with opioid use disorders leaving jails. This study will estimate XR-NTX's effectiveness relative to existing standards of care, including counseling-only treatment-as-usual and methadone maintenance.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Andiea Harris; Daniel Selling; Charles Luther; Jason Hershberger; Joan Brittain; Samuel Dickman; Alvin Glick; Joshua D Lee Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch Journal: Drug Alcohol Depend Date: 2006-10-11 Impact factor: 4.492
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Angela Di Paola; Thomas Lincoln; Daniel J Skiest; Maureen Desabrais; Frederick L Altice; Sandra A Springer Journal: Contemp Clin Trials Date: 2014-09-18 Impact factor: 2.226
Authors: Andrea K Finlay; Alex H S Harris; Joel Rosenthal; Jessica Blue-Howells; Sean Clark; Jim McGuire; Christine Timko; Susan M Frayne; David Smelson; Elizabeth Oliva; Ingrid Binswanger Journal: Drug Alcohol Depend Date: 2016-01-24 Impact factor: 4.492
Authors: Robert P Schwartz; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Jerome H Jaffe Journal: J Subst Abuse Treat Date: 2018-11-19
Authors: Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum Journal: Int J Environ Res Public Health Date: 2022-04-30 Impact factor: 4.614
Authors: Redonna K Chandler; Matthew S Finger; David Farabee; Robert P Schwartz; Timothy Condon; Laura J Dunlap; Gary A Zarkin; Kathryn McCollister; Ryan D McDonald; Eugene Laska; David Bennett; Sharon M Kelly; Maureen Hillhouse; Shannon G Mitchell; Kevin E O'Grady; Joshua D Lee Journal: Contemp Clin Trials Date: 2016-05-11 Impact factor: 2.226
Authors: Melissa Velasquez; Mara Flannery; Ryan Badolato; Alexandria Vittitow; Ryan D McDonald; Babak Tofighi; Ann R Garment; Jonathan Giftos; Joshua D Lee Journal: Addict Sci Clin Pract Date: 2019-10-01